

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1102281
<b>Application Number:</b>	10596504
<b>Confirmation Number:</b>	7396
<b>Title of Invention:</b>	TREATMENT OF CONDITIONS THAT PRESENT WITH LOW BONE MASS BY CONTINUOUS COMBINATION THERAPY WITH SELECTIVE PROSTAGLANDIN EP4 RECEPTOR AGONISTS AND AN ESTROGEN
<b>First Named Inventor:</b>	Hua Zhu KE
<b>Customer Number:</b>	28523
<b>Filer:</b>	Martha Grace Munchhof/Madeline Deveran
<b>Filer Authorized By:</b>	Martha Grace Munchhof
<b>Attorney Docket Number:</b>	
<b>Receipt Date:</b>	05-JUL-2006
<b>Filing Date:</b>	
<b>Time Stamp:</b>	14:04:24
<b>Application Type:</b>	U.S. National Stage under 35 USC 371
<b>International Application Number:</b>	

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	Information Disclosure Statement (IDS) Filed	iPC23170A-IDS7-7-06.pdf	143302	no	2

<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
2	Information Disclosure Statement (IDS) Filed	iPC23170A-IDS-CitationList.pdf	320307	no	3
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
3	NPL Documents	iPC23170A-Arrenbrech-Effectstrans-dermalpdf.pdf	204750	no	8
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	iPC23170A-Black-RaloxifenLY139481.pdf	4836510	no	7
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	iPC23170A-Capony-InVivo.pdf	5952094	no	19
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	iPC23170A-Clark-EstrogenReceptorAnti-Estrogen.pdf	612843	no	12
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	iPC23170A-Delmas-Effects-Raloxifene.pdf	162042	no	7
<b>Warnings:</b>					
<b>Information:</b>					
8	Foreign Reference	iPC23170A-EP378404.pdf	1508743	no	22
<b>Warnings:</b>					
<b>Information:</b>					
9	Foreign Reference	iPC23170A-EP605193.pdf	712209	no	17
<b>Warnings:</b>					
<b>Information:</b>					

10	Foreign Reference	iPC23170A-EP802183.pdf	1324013	no	97
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	iPC23170A-Gauthier-Journal MedChem.pdf	1638506	no	6
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	iPC23170A-Hansson-Perfora tedCoated.pdf	483702	no	3
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	iPC23170A-ScripNo1812-13. pdf	427877	no	3
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	iPC23170A-Shen-EffectsRec iprocalTreatment.pdf	1505234	no	8
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	iPC23170A-Siris-Identificatio nFracture-JAMA.pdf	2164816	no	8
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	iPC23170A-Tang-Restoring MaintainingBone.pdf	1204928	no	12
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	iPC23170A-WHO-Assesmen tFractureRisk.pdf	4541638	no	69
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	iPC23170A-Willson-3-4-Diph .pdf	1331038	no	3
<b>Warnings:</b>					
<b>Information:</b>					

19	Foreign Reference	IPC23170A-WO1995010513. pdf	3120001	no	98
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			32194553		
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>					